DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: OCREVUS (ocrelizumab)
*****************************************************
#Post#: 2117--------------------------------------------------
Two new studies of progressive MS announced, as well as new Ocre
vus data on long-term disability
By: agate Date: June 14, 2018, 3:10 pm
---------------------------------------------------------
From Business Wire, June 14, 2018, an article based on an
announcement from Genentech, "Genentech Announces New Ocrevus
Data on Long-Term Disability Benefits in Primary Progressive
Multiple Sclerosis and Initiation of Two Global Studies in
Progressive MS":
HTML https://www.businesswire.com/news/home/20180613006368/en/Genentech-Announces-New-OCREVUS-Ocrelizumab-Data-Long-Term
The second new study mentioned in the article might be of
interest for anyone with SPMS:
[quote]
[font=helvetica neue]The second study, named CONSONANCE, will
evaluate the efficacy of OCREVUS in the complete spectrum of
progressive MS (PPMS and secondary progressive MS (SPMS)). The
CONSONANCE study will measure the long-term effectiveness of
OCREVUS in progressive MS with novel composite disability
endpoints, including No Evidence of Progression (NEP) and No
Evidence of Progression or Active Disease (NEPAD), in addition
to a wide range of patient-relevant measures and advanced MRI
outcomes. The four-year, Phase IIIb study is currently enrolling
600 people with PPMS or SPMS (in a 1:1 ratio) from across 26
countries. The study will also explore whether
technology-enabled, continuous sensor-based and
self-administered measures may detect changes in disability
progression earlier than conventional clinical
measures.[/font][/quote]
*****************************************************